Paper12373594
Platinum drugs in the treatment of non-small-cell lung cancer.
Cosaert J and 1 other. Br J Cancer, 2002. Cited by 78 papers, by iCite.
Cite this record
ConductScience Library. Platinum drugs in the treatment of non-small-cell lung cancer. Papers, record 12373594. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12373594
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Carboplatin | |
| Cisplatin | |
| Clinical Trials as Topic | |
| Combined Modality Therapy | |
| Etoposide | |
| Humans | |
| Paclitaxel |
Source PubMed
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10561376 | Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561376 | PubMed |
| 2 | 7844593 | Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. | J Clin Oncol | 1995 | https://conductscience.org/library/papers/7844593 | PubMed |
| 3 | 10864225 | Preclinical perspectives on platinum resistance. | Drugs | 2000 | https://conductscience.org/library/papers/10864225 | PubMed |
| 4 | 2171622 | Long-term sequelae of treatment for testicular germ cell tumours. | Br J Cancer | 1990 | https://conductscience.org/library/papers/2171622 | PubMed |
| 5 | 10448284 | Guidelines for anti-emetic therapy: acute emesis. | Eur J Cancer | 1999 | https://conductscience.org/library/papers/10448284 | PubMed |
| 6 | 2169587 | A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. | N Engl J Med | 1990 | https://conductscience.org/library/papers/2169587 | PubMed |
| 7 | 1324895 | Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. | Int J Radiat Oncol Biol Phys | 1992 | https://conductscience.org/library/papers/1324895 | PubMed |
| 8 | 2157554 | A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2157554 | PubMed |
| 9 | 9667264 | Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9667264 | PubMed |
| 10 | 10585004 | Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. | Semin Oncol | 1999 | https://conductscience.org/library/papers/10585004 | PubMed |
| 11 | 11843242 | Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? | Ann Oncol | 2001 | https://conductscience.org/library/papers/11843242 | PubMed |
| 12 | 10550150 | Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10550150 | PubMed |
| 13 | 6540685 | Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. | Eur J Cancer Clin Oncol | 1984 | https://conductscience.org/library/papers/6540685 | PubMed |
| 14 | 3880810 | Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens. | J Clin Oncol | 1985 | https://conductscience.org/library/papers/3880810 | PubMed |
| 15 | 11279780 | Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). | Cochrane Database Syst Rev | 2001 | https://conductscience.org/library/papers/11279780 | PubMed |
| 16 | 2547028 | Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2547028 | PubMed |
| 17 | 9428487 | Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. | Cancer | 1998 | https://conductscience.org/library/papers/9428487 | PubMed |
| 18 | 8573296 | Comparative adverse effect profiles of platinum drugs. | Drug Saf | 1995 | https://conductscience.org/library/papers/8573296 | PubMed |
| 19 | 8718420 | Current chemotherapy of advanced non-small cell lung cancer. | Anticancer Drugs | 1995 | https://conductscience.org/library/papers/8718420 | PubMed |
| 20 | 9541678 | Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | Ann Oncol | 1998 | https://conductscience.org/library/papers/9541678 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42272260 | A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer. | Oncol Rep | 2026 | https://conductscience.org/library/papers/42272260 | PubMed |
| 36498837 | Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36498837 | PubMed |
| 36358986 | Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations. | Biomolecules | 2022 | https://conductscience.org/library/papers/36358986 | PubMed |
| 36358724 | The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36358724 | PubMed |
| 35875329 | The emergence of nanoporous materials in lung cancer therapy. | Sci Technol Adv Mater | 2022 | https://conductscience.org/library/papers/35875329 | PubMed |
| 35057025 | pH-Responsive Liposomes of Dioleoyl Phosphatidylethanolamine and Cholesteryl Hemisuccinate for the Enhanced Anticancer Efficacy of Cisplatin. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35057025 | PubMed |
| 34856706 | A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. | Cancer Res Treat | 2022 | https://conductscience.org/library/papers/34856706 | PubMed |
| 34502361 | Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34502361 | PubMed |
| 34400945 | Effect of Menadione and Combination of Gemcitabine and Cisplatin on Cancer Stem Cells in Human Non-small Cell Lung Cancer (NSCLC) Cell Line A549. | Iran J Pharm Res | 2021 | https://conductscience.org/library/papers/34400945 | PubMed |
| 33884290 | Organ-restricted vascular delivery of nanoparticles for lung cancer therapy. | Adv Ther (Weinh) | 2020 | https://conductscience.org/library/papers/33884290 | PubMed |
| 33805467 | Targeting AKT/mTOR and Bcl-2 for Autophagic and Apoptosis Cell Death in Lung Cancer: Novel Activity of a Polyphenol Compound. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/33805467 | PubMed |
| 32843536 | Mammalian copper homeostasis requires retromer-dependent recycling of the high-affinity copper transporter 1. | J Cell Sci | 2020 | https://conductscience.org/library/papers/32843536 | PubMed |
| 31385067 | New dinuclear palladium(II) complexes with benzodiazines as bridging ligands: interactions with CT-DNA and BSA, and cytotoxic activity. | J Biol Inorg Chem | 2019 | https://conductscience.org/library/papers/31385067 | PubMed |
| 30695050 | Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. | PLoS One | 2019 | https://conductscience.org/library/papers/30695050 | PubMed |
| 29536182 | Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer. | Pharm Res | 2018 | https://conductscience.org/library/papers/29536182 | PubMed |
| 29247315 | Development of a copper-clioquinol formulation suitable for intravenous use. | Drug Deliv Transl Res | 2018 | https://conductscience.org/library/papers/29247315 | PubMed |
| 29088858 | Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. | Oncotarget | 2017 | https://conductscience.org/library/papers/29088858 | PubMed |
| 27342417 | ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. | Eur J Nucl Med Mol Imaging | 2016 | https://conductscience.org/library/papers/27342417 | PubMed |
| 26216446 | Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. | Naunyn Schmiedebergs Arch Pharmacol | 2015 | https://conductscience.org/library/papers/26216446 | PubMed |
| 25897409 | Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. | Springerplus | 2015 | https://conductscience.org/library/papers/25897409 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EPO | 2056 | PubTator's text mining | https://conductscience.org/library/genes/2056 | NCBI Gene |
| ERCC1 | 2067 | PubTator's text mining | https://conductscience.org/library/genes/2067 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12373594
GET https://conductscience.org/api/papers/v1/12373594/references?page=2